Medication evidence profile
Ipratropium
Clinical overview
Ipratropium has public medication-list entries in Yamada-ABS 2023, BAAS 2019, GABS 2018, and CALS 2022 Table 4. These are 4 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | Not listed |
| Yamada-ABS | 2 |
| BAAS | 3 |
| Swe-ABS | Not listed |
| GABS | 1 |
| KABS | Not listed |
| CALS | 1 |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
Other names used in the sources
Ipratropium inhalative, ipratropium †
How to interpret the evidence
4 of 7 public source versions contain an explicit medication-list entry for ipratropium.
The recorded values differ across the source rows for ipratropium. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.
None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.
Source labels and provenance · 4 observations
- Yamada Pharmacological Anticholinergic Burden Scale 2023
Source label: Ipratropium. Published value: 2.
Source version: YAMADA-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
Observation: YAMADA_ABS_2023_R0046; rating state: published_rating. - Brazilian Anticholinergic Activity Scale 2019
Source label: Ipratropium. Published value: 3.
Source version: BAAS-2019
Source location: RC4 source recovery; recovery_scope=primary_table_complete
Observation: BAAS_2019_R0029; rating state: published_rating. - German Anticholinergic Burden Score 2018
Source label: Ipratropium inhalative. Published value: 1.
Source version: GABS-2018
Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
Observation: GABS_2018_R0053; rating state: published_rating. - CALS 2022 - primary final Table 4
Source label: Ipratropium. Published value: 1.
Source version: CALS-2022-primary-table4
Source location: Table 4; literal capture row 10; displayed table row 2; displayed column 3
Observation: CALS2022_T4_0010; rating state: published_final_table_rating.
Dose, route, and formulation notes
GABS 2018 uses the source label “Ipratropium inhalative”. This qualification remains attached to that row. GABS-2018
What this page does not establish
- No medication-list entry is available here from JARS 2025, Swe-ABS 2023, and KABS 2020 open validation supplement. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- No route inference unless present in the source label.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
- Nery RT, Reis AMM. Development of a Brazilian anticholinergic activity drug scale. Einstein (Sao Paulo). 2019;17(2):eAO4435. doi:10.31744/einstein_journal/2019AO4435. Open source
- Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
- Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic Load Scale: an updated anticholinergic burden scale. Comparison with the ACB Scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. doi:10.3390/jpm12020207. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Ipratropium
Ask about this medication